Additional studies are necessary to better define the pattern of co-expression of LAG-3, TIM-3, PD-1 and other immune checkpoints on NK and T cells in AML patients and its relevance in their response to checkpoint blockade. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.